Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid

Infectious Disease Clinics of North America

Volumn 17, Issue 3, 2003, Pages 479-501

  Craig, William A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFMENOXIME; CEFONICID; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DAPTOMYCIN; GLYCOPEPTIDE; KETOLIDE; LINEZOLID; MACROLIDE; METICILLIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG USE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; REVIEW; SPECIES DIFFERENCE; STAPHYLOCOCCUS;

EID: 0347694556     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(03)00065-5     Document Type: Review

References (103)

1. Eagle H, Musselman AD. The slow recovery of bacteria from the toxic effects of penicillin. J Bacteriol 1949;58:475-90.
2. Eagle H, Fleishman R, Musselman AD. Effect of schedule of administration on the therapeutic efficacy of penicillin. Am J Med 1950;9:280-99.
3. Rolinson GN. Plasma concentrations of penicillin in relations to the antibacterial effect. In: Davies DS, Prichard BNC, editors. Biological effects of drugs in relation to their plasma concentration. Baltimore: University Park Press; 1973. p. 183-9.
4. Craig WA. Pharmacokineitc/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
5. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
6. Craig WA, Ebert S. Kinetics and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1991;74:15-22.
7. McDonald PJ, Craig WA, Kunin CM. Persistent effects of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977;135:217-23.
8. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
9. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. 4th edition. Baltimore: Williams & Wilkins; 1996. p. 296-329.
10. Cars O, Odenholt-Tornqvist I. The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993;319(suppl D):159-66.
11. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981;3:38-44.
12. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-98.
13. Bustamante CI, Drusano GL, Tatem BA, Standiford HC. Post-antibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:678-82.
14. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetics parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
15. Gerber AU, Craig WA, Brugger H-P, Feller C, Vastola AP, Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983;147:910-7.
16. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125-9.
17. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, editors. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker; 2002. p. 1-22.
18. Lutsar I, McCracken GH, Friedland IA. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;42:2650-5.
19. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of antimicrobials in meningitis. Infect Dis Clin North Am 1999;13:595-618.
20. Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med 1997;3:170-4.
21. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41:1399-402.
22. Georges H, Leroy O, Alfandara S, Guery B, Roussel-Delvallez M, Dhennain C, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-8.
23. Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6.
24. Eagle H, Fleishman R, Levy M. "Continuous" vs. "discontinuous" therapy with penicillin: the effect of the interval between injections on the therapeutic efficacy. N Engl J Med 1953;248:481-8.
25. Schmidt LH, Walley A. The influence of the dosage regimen on the therapeutic effectiveness of penicillin G in experimental lobar pneumonia. J Pharmacol Exp Ther 1951;103:479-88.
26. Frimodt-Møller N, Benton MW, Thomsen WF. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 1986;154:511-7.
27. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relationships at several dosing intervals in murine peritonitis and thigh: infection models. J Infect Dis 1989;159:281-92.
28. Craig W, Ebert S, Watanabe Y. Differences in time above MIC (T > MIC) required for efficacy of beta-lactams in animal model infections [abstract 1485]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington: American Society for Microbiology; 1993. p. 391.
29. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
30. Andes D, Walker R, Ebert S, Craig W. Increasing protein binding of cefonicid enhances its in vivo activity in an animal infection model. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington: American Society for Microbiology; 1994. p. 147.
31. Andes DR, Craig WA. Impact of extended-spectrum beta-lactamase (ESBL) production on the activity of cefepime in a murine-thigh infection model. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington: American Society for Microbiology; 2001. p. 26.
32. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Lorian V, editor. Antibiotics in laboratory medicine. 3rd edition. Baltimore: Williams & Wilkins; 1991. p. 367-402.
33. Van Ogtrop ML, Andes D, Craig WA. In vivo antimicrobial activity of MK-0826, a new carbapenem, against various gram-negative bacteria and Staphylococcus aureus. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 1999. p. 27.
34. Craig WA, Andes DR. In vivo pharmacodynamic activity of faropenem against Streptococcus pneumoniae. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington: American Society for Microbiology; 2001. p. 34.
35. Fantin B, Leggett J, Ebert S. Craig WA. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 1991;35:1413-22.
36. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9.
37. Urban A, Andes D, Craig WA. In-vivo activity of cefpodoxime against penicillin-resistant pneumococci [abstract]. In: Final Program and Abstracts of the 19th International Congress of Chemotherapy, Montreal, July 16-21, 1995.
38. Andes DR, Jacoby G, Craig WA. Impact of extended-spectrum beta-lactamase (ESBL) production in Klebsiella pneumoniae on activity of four beta-lactams in a murine-thigh infection model [abstract]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 1995. p. 12.
39. Roosendaal R, Bakker-Woudenberg IAJM, van den Bergh JC, van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenia rats. Antimicrob Agents Chemother 1986;30:403-8.
40. Craig WA, Ebert S, Leggett J, Redington J. Effect of neutrophils on in vivo potency of antibiotics against Klebsiella pneumoniae [abstract]. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (Atlanta). Washington: American Society for Microbiology; 1990. p. 112.
41. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-8.
42. Fraschini F, Scaglione F. Study on the relationship between pharmacokinetics and antibacterial activity: comparison between ceftriaxone and cefotaxime within the respiratory tract. Chemotherapy 1989;35:77-82.
43. Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predicative of efficacy. J Antimicrob Chemother 1999;43(suppl A):55-63.
44. Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;23:1231-44.
45. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
46. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50:425-8.
47. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001;47:129-40.
48. Dagan R, Hoberman A, Johnson C, Leibovitz EL, Arguedas A, Rose FV, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001;20:829-37.
49. Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media: effectiveness of erythromycin estoiate, triple sulfonamide, ampicillin, erythromycin estolate-triple sulfonamide, and placebo in 280 patients with acute otitis media under two and one-half years of age. Clin Pediatr 1972;11: 205-14.
50. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
51. Dagan R, Johnson CE, McLinn S, Abughali N, Feris J, Leibovitz E, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000;19:95-104.
52. Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43-50.
53. NCCLS Document M100-S11: Performance standards for antimicrobial susceptibility testing; eleventh informational supplement. Philadelphia (PA): NCCLS; 2001;21:1.
54. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Applebaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobials agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother 2000;44:3243-5.
55. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002; 113:120-6.
56. Vu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-7.
57. File TM Jr. Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate. Int J Antimicrob Agents 2002; 20:235-47.
58. Craig WA. The future - can we learn from the past? Diagn Microbiol Infect Dis 1997;27:49-53.
59. Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan D, Musher DM, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus Pneumoniae Therapeutic Working Group. Pediatr Infect Dis 1999;18:1-9.
60. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000;123:S1-32.
61. Bartlett JG, Dowell SF, Mandell LA, File TM Jr. Musher DM, Fine MJ. Guidelines from the Infectious Diseases Society of America: practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82,
62. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001;163:1730-54.
63. Leder K, Turnidge J, Korman T, Grayson M. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 1999;43:113-8.
64. Craig W. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995;14:636-42.
65. Raber S, Legget J, Kohlhepp S, Dworkin R, Gilbert D. Continuous vs. intermittent infusion of oxacillin in patients with staphylococcal infection [abstract A104]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington: American Society for Microbiology; 1996. p. 20.
66. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003;114:723-8.
67. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33.
68. Paterson D, Ko W, Von Gottberg A, Casellas J, Mulazimoglu L, Klugman K, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
69. Rupp M, Fey P. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353-65.
70. Craig WA, Ebert S. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-83.
71. Lagast H, Meunier-Carpentier F, Klastersky J. Treatment of gram-negative bacillary septicaemia with cefoperazone. Eur J Clin Microbiol 1983;2:554-8.
72. MacGowan A, Bowker K. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998;35:391-402.
73. Nicolau D, McNabb J, Lacy M. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504.
74. Ebert S, Leggett J, Vogelman B. In vivo cidal activity and pharmacokinetics parameters (PKPs) for vancomycin against methicillin-susceptible (MSSA) and -resistant (MRSA) S. aureus. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington: American Society for Microbiology; 1987. p. 173.
75. Dudley M, Griffith D, Corcoran E, Liu C, Sorensen K, Tembe V, et al. Pharmacokinetic-pharmacodynamic (PK-PD) indices for vancomycin treatment of susceptible (VSSA) and intermediate (VISA) S. aureus in the neutropenic murine thigh model. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 1999. p. 49.
76. Pavie J, Lefort A, Ploy M-C, Massias L, Chau F, Garry L, et al. Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother 2003;47:2018-21.
77. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990;34:510-4.
78. Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997;41:2497-501.
79. Duffull SB, Begg EJ, Chambers ST, Barclay ML. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 1994;38:2480-2.
80. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay of vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996;38:589-97.
81. Knudsen JD, Fuursted K, Espersen F, Frimodt-Moller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to the pharmacokinetics parameters in the mouse peritonitis model. Antimicrob Agents Chemother 1997:41:1910-5.
82. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000;44:1247-54.
83. Craig WA, Andes DR. In vivo pharmacodynamics of BB-83698, a deformylase inhibitor. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington: American Society for Microbiology; 2001. p. 206.
84. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring systemic for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57(suppl 2):4-9.
85. Georges H, Leroy O, Alfandara S, Guery B, Roussel-Delvallez M, Dhennain C, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-8.
86. Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6.
87. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40:696-700.
88. Byl B, Jacobs F, Wallemacq P, Rossi C, de Francquen P, Cappello M, et al. Vancomycin penetration of uninfected pleural fluid exudates after continuous or intermittent infusion. Antimicrob Agents Chemother 2003;47:2015-7.
89. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45:2460-7.
90. Moise PA, Schentagg JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16(suppl 1):S31-4.
91. Wunderink R, Cammarata SK, Croos-Darbera RV, Kollef M. Linezolid vs vancomycin: predictors of outcome in methicillin-resistant Staphylococcus aureus nosocomial pneumonia. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America. Alexandra, VA: Infectious Disease Society of America; 2002. p. 76.
92. Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002;50:1017-26.
93. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-27.
94. Munckhof WJ, Giles C, Turnidge JD. Post-antibiotic growth suppression of linezolid against gram-positive bacteria. J Antimicrob Chemother 2001;47:879-83.
95. Andes D, Peng J, Craig WA. In-vivo characterization of the pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9.
96. Jacqueline C, Batard E, Perez L, Boutoille D, Hamel A, Caillon J, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002;46:3706-11.
97. Humphrey WR, Shattuck MH, Zielinski RJ, Kuo MS, Biermacher JJ, Smith DP, et al. Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae induced acute otitis media. Antimicrob Agents Chemother 2003;47:1355-63.
98. Pelton SI, Figueira M, Albut R, Stalker D. Efficacy of linezolid in experimental otitis media. Antimicrob Agents Chemother 2000;44:654-7.
99. Conte JE, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;26:1475-80.
100. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
101. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159-68.
102. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T, the Linezolid Community Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002;34:720-8.
103. Bodey GP, Ketchel SJ, Rodriguez V. A randomized trial of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.